Advertisement
The pharma giant's acquisition of Point Biopharma reshapes the competitive landscape for PSMA-targeted treatments — and puts pressure on rivals to move fast.
As demand for short-lived isotopes surges, operators face a capital-intensive buildout with no margin for error.
Investors are betting on the next generation of theranostic platforms, with seed rounds reaching record highs.
Perspectives from nuclear medicine leaders
Market moves, clinical milestones, executive changes, and regulatory updates — curated for radiopharmacy and nuclear medicine professionals.
